Piper Sandler Reiterates Overweight on Axsome Therapeutics, Maintains $258 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 64.4%

Neg 0% Neu 64.4% Pos 0%

Piper Sandler analyst David Amsellem reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and maintains $258 price target.